Date: 2013-04-08
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Vivalis (France) GSK (UK)
Therapeutic area: Infectious diseases
Type agreement: R&D
licensing
Action mechanism:
Disease: undisclosed viral disease
Details: Vivalis has signed an EB66® cell line research services and license option agreement with GSK to establish the feasibility of producing a new viral vaccine against an important viral disease using EB66® with an option to license EB66® cell line for similar viruses of the same family. This is the second EB66® cell line agreement with GSK following the agreement in 2007 on the development of influenza vaccines using the EB66® cell line.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
